AB0582 Soluble triggering receptor expressed on myeloid cells-1 (STREM-1) and adrenomedulin are elevated in patients with systemic lupus erythematosus. (12th June 2018)

• Record Type: Journal Article
• Authors: Jeremic, I.; Stojanovic, N.; Stanojevic, Z.; Jovanovic, B.; Tosic, J.; Vidicevic, S.; Isakovic, A.
• Is Part Of: Annals of the rheumatic diseases. Volume 77(2018)Supplement 2
• Page Start: 1444
• Page End: 1444
• Publication Date: 2018-06-12
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2018-eular.6570
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Adrenomedulin is a peptide firstly isolated from human phaeochromocytoma with vasodilatory effects. Secretion of adrenomedulin is modified by inflammatory cytokines and it may be important as a suppressor of lupus nephritis activity. Triggering receptor expressed on myeloid cells-1 (TREM) is a member of immunoglobulin superfamily clearly elevated in inflammatory conditions. Some subgroups of patients with systemic lupus erythematosus-SLE may have especially elevated levels of s-TREM. Objectives: The aim of this study was to examine adrenomedulin and s-TREM levels in patients with SLE and healthy controls and to assess their relation with SLE disease activity index-SLEDAI Methods: Serum samples from 50 SEL patients and 40 healthy blood donors were analysed. Serum levels of adrenomedulin, s-TREM, complement components C3 and C3, and anti-dsDNA antibodies were measured Results: Patients with SLE had higher adrenomedulin (9.8±4.5 vs. 15.3±7.2 pg/mL, p<0.05) and s-TREM (11.7±4.1 vs. 20.3±13.1 pg/mL) (p<0.05) levels. s-TREM showed correlation with anti-dsDNA antibodies (ρ=0.405, p<0.05) and SLEDAI score (ρ=0.386, p<0.001). In multivariate analysis s-TREM did not appear as an independent predictor of SLEDAI score, while only anti-dsDNA antibodies were significant in multivariate analysis. Conclusions: Increased adrenomedulin and s-TREM are found in lupus sera. Despite of correlation with SLEDAI score, s-TREM is not better then anti-dsDNA antibodies as a predictor of SLE disease activity. Disclosure of Interest: None declared